<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11271">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02960204</url>
  </required_header>
  <id_info>
    <org_study_id>IDN-6556-14</org_study_id>
    <nct_id>NCT02960204</nct_id>
  </id_info>
  <brief_title>Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension</brief_title>
  <acronym>ENCORE-PH</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Conatus Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Conatus Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled trial involving subjects
      with NASH cirrhosis and severe portal hypertension (defined as HVPG ≥12 mmHg as determined
      by the central reader assigned to this study). Upon successful screening, subjects will be
      randomized to receive either emricasan 50 mg BID, 25 mg BID, or 5 mg BID or matching placebo
      BID.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Hepatic Venous Pressure Gradient (HVPG)</measure>
    <time_frame>Week 24</time_frame>
    <description>To assess the mean change from baseline in hepatic venous pressure gradient (HVPG)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects with Treatment Emergent Adverse Events</measure>
    <time_frame>Baseline, Week 4, 8, 12, 16, 20, and 24</time_frame>
    <description>To assess the differences in adverse events between emricasan and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of HVPG response using a 20% reduction from baseline</measure>
    <time_frame>Week 24</time_frame>
    <description>To assess the proportion of subjects who have at least a 20% reduction from baseline in HVPG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caspase 3/7</measure>
    <time_frame>Baseline, Week 4, 8, 12, 16, 20, and 24</time_frame>
    <description>To assess whether emricasan compared to placebo decreases Caspase 3/7 biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase (ALT)</measure>
    <time_frame>Baseline, Week 4, 8, 12, 16, 20, and 24</time_frame>
    <description>To assess whether emricasan compared to placebo decreases non-specific (ALT) biomarkers</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Emricasan (5 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (5 mg) twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Emricasan (25 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (25 mg) twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Emricasan (50 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (50 mg) twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with a matching placebo twice a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emricasan</intervention_name>
    <arm_group_label>Emricasan (5 mg)</arm_group_label>
    <arm_group_label>Emricasan (25 mg)</arm_group_label>
    <arm_group_label>Emricasan (50 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects 18 years or older, able to provide written informed consent
             and able to understand and willing to comply with the requirements of the study.

          -  Cirrhosis due to NASH with exclusion of other causes of cirrhosis (e.g. chronic viral
             hepatitis, alcoholic liver disease, etc.)

          -  Compensated cirrhosis OR Decompensated cirrhosis with no more than 1 prior
             significant decompensating event

          -  Severe portal hypertension defined as HVPG ≥12 mmHg

          -  Subjects who are on NSBB, nitrates, diuretics, lactulose, rifaximin, or statins must
             be on a stable dose for at least 3 months prior to Day 1

          -  Willingness to utilize effective contraception (for both males and females of
             childbearing potential) from Screening to 4 weeks after the last dose of study drug

        Exclusion Criteria:

          -  Evidence of severe decompensation

          -  Severe hepatic impairment defined as a Child-Pugh score ≥10

          -  ALT or AST &gt;5 times upper limit of normal (ULN) during screening

          -  Estimated creatinine clearance &lt;30 mL/min

          -  Prior transjugular intrahepatic portosystemic shunt or other porto-systemic bypass
             procedure

          -  Known portal vein thrombosis

          -  Symptoms of biliary colic, e.g. due to symptomatic gallstones, within the last 6
             months, unless resolved following cholecystectomy

          -  Current use of medications that are considered inhibitors of OATP1B1 and OATP1B3
             transporters

          -  Alpha-fetoprotein &gt;200 ng/mL

          -  History or presence of clinically concerning cardiac arrhythmias, or prolongation of
             screening (pre-treatment) QTcF interval of &gt;500 msec

          -  History of or active malignancies, other than those successfully treated with
             curative intent and believed to be cured

          -  Significant systemic or major illness other than liver disease

          -  Use of controlled substances (including inhaled or injected drugs) or non-prescribed
             use of prescription drugs within 1 year of screening

          -  If female: planned or known pregnancy, positive urine or serum pregnancy test, or
             lactating/breastfeeding

          -  Previous treatment with emricasan or active investigational medication (except
             methacetin) in a clinical trial within 3 months prior to Day 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hagerty, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Conatus Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Grubbs</last_name>
    <phone>(858) 376-2627</phone>
    <email>lgrubbs@conatuspharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Liver Research Institute</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IMIC Inc.</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Piedmont Atlanta Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Iowa Digestive Disease Center</name>
      <address>
        <city>Clive</city>
        <state>Iowa</state>
        <zip>50325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Digestive and Liver Disease Specialists; Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Minnesota Gastroenterology, PA</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansas City Gastroenterology and Hepatology</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center, Duke South Clinics</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Einstein Healthcare Network</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Clinical Research Institute</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Liver Therapies - Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>American Research Corporation at the Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Digestive and Liver Disease Specialists</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bon Secours Liver Institute of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 15, 2017</lastchanged_date>
  <firstreceived_date>July 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cirrhosis</keyword>
  <keyword>Portal Hypertension</keyword>
  <keyword>Non-alcoholic Steatohepatitis</keyword>
  <keyword>Liver cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Caspase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share this data with outside researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
